Anti-cancer drugsHumansDrug ResistanceNeoplasmPyridinesLiver Neoplasms
A genome-wide screen identified ARHGAP35 as a regulator of regorafenib resistance in liver cancer.
Kun Chen, Miaomiao Zhang, Yuexin Liu, Zhengnan Dong, Yaoji Liang, Jinzhang Zeng, Jie Liu
Published: 202610.1097/CAD.0000000000001775
Abstract
Regorafenib, a multikinase inhibitor, is widely used to treat hepatocellular carcinoma. However, chemoresistance poses a significant challenge to its long-term efficacy. This study conducted a genome-wide CRISPR/Cas9 knockout screen in liver cancer c…
Preview only. Read the full abstract at the source